Related references
Note: Only part of the references are listed.Comprehensive Analysis of Ferroptosis-Related Markers for the Clinical and Biological Value in Gastric Cancer
Yanfei Shao et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2021)
The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment
Hong Zhang et al.
ACTA PHARMACEUTICA SINICA B (2021)
A Nomogram for Predicting Pathological Complete Response to Neoadjuvant Chemoradiotherapy Using Semiquantitative Parameters Derived From Sequential PET/CT in Locally Advanced Rectal Cancer
Dae Hee Pyo et al.
FRONTIERS IN ONCOLOGY (2021)
Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram
Hao Cui et al.
FRONTIERS IN ONCOLOGY (2021)
The Multifaceted Role of Aldehyde Dehydrogenases in Prostate Cancer Stem Cells
Jakob Pueschel et al.
CANCERS (2021)
Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges
J. Heil et al.
ANNALS OF ONCOLOGY (2020)
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Laura M. Spring et al.
CLINICAL CANCER RESEARCH (2020)
Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers
Rushdia Zareen Yusuf et al.
BLOOD (2020)
Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial
Han-Byoel Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence.
Nicholas J. Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Identification of Novel Glycolysis-Related Gene Signatures Associated With Prognosis of Patients With Clear Cell Renal Cell Carcinoma Based on TCGA
Chengjiang Wu et al.
FRONTIERS IN GENETICS (2020)
Identification of ALDH3A2 as a novel prognostic biomarker in gastric adenocarcinoma using integrated bioinformatics analysis
Zhenhua Yin et al.
BMC CANCER (2020)
Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: A retrospective exploratory analysis
Sandra M. Swain et al.
CANCER RESEARCH (2020)
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
Sara A. Hurvitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy
Mariko Asaoka et al.
EJSO (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells
Giuseppe Vassalli
STEM CELLS INTERNATIONAL (2019)
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
Andreas Schneeweiss et al.
EUROPEAN JOURNAL OF CANCER (2018)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
J. A. Alberro et al.
LANCET ONCOLOGY (2018)
Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy
Anna Weiss et al.
BREAST CANCER RESEARCH (2018)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors
Mauricio Rodriguez-Torres et al.
CLINICAL & EXPERIMENTAL METASTASIS (2016)
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Luca Gianni et al.
LANCET ONCOLOGY (2016)
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes A Meta-Analysis
Kristine R. Broglio et al.
JAMA ONCOLOGY (2016)
Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets
David W. Clark et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy
Misbat Chaudry et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: A sub-study of EORTC 10994/BIG 1-00 phase III trial
F. Fei et al.
EUROPEAN JOURNAL OF CANCER (2015)
Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies
Alfredo Berruti et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
A. Schneeweiss et al.
ANNALS OF ONCOLOGY (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Aldehyde Dehydrogenase Activity of Breast Cancer Stem Cells is Primarily Due to Isoform ALDH1A3 and Its Expression is Predictive of Metastasis
Paola Marcato et al.
STEM CELLS (2011)
Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
M. Tanioka et al.
BRITISH JOURNAL OF CANCER (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy
AM Gonzalez-Angulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
